MedPath

Normalizing CO2 in Chronic Hyperventilation by a Novel Breathing Mask: A Pilot Study

Not Applicable
Completed
Conditions
Dysfunctional Breathing
Respiratory Alkalosis
Hyperventilation
Chronic Idiopathic Hyperventilation
Registration Number
NCT01575665
Lead Sponsor
University of Aarhus
Brief Summary

Background: Chronic Idiopathic Hyperventilation (CIH) is a form of dysfunctional breathing which has proven hard to treat effectively. The investigators hypothesised that by periodically inducing normocapnia over several weeks, it would be possible to raise the normal resting level/set point of CO2 and achieve a reduction of symptoms.

Methods: Six CIH patients were treated two hours a day for four weeks with a novel breathing mask. The mask was used to induce normocapnia in these chronically hypocapnic patients.

Capillary blood gases (PcCO2, pH, Standard Base Excess (SBE) etc.) were measured at baseline and once each week at least three hours after mask use, as well as spirometric values, breath holding tolerance and hyperventilation symptoms as per the Nijmegen Questionnaire (NQ),.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6
Inclusion Criteria

Chronic idiopathic hyperventilation, i.e.:

  • PCO2 level below 4.7 kPa AND
  • SBE value more negative than -1.0
Exclusion Criteria
  • Oxygen saturation of 95% or lower at rest

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Blood gas and acid/base statusOnce every week in the treatment period of four weeks

pH, PCO2, PO2, Standard Base Excess

Secondary Outcome Measures
NameTimeMethod
Breath Hold Toleranceonce a week
Spirometric valuesonce a week

FEV1, FVC

Hyperventilation symptomsonce a week

Nijmegen Questionnaire

Trial Locations

Locations (1)

Aarhus University Hospital

🇩🇰

Aarhus, Denmark

Aarhus University Hospital
🇩🇰Aarhus, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.